ABSTRACT Historically, Salmonella vaccines have been either live attenuated or killed bacterin vaccines that fail to offer cross-serogroup protection, which limits risk mitigation and protection of consumers. Subunit recombinant vaccines which possess highly conserved antigens offer potential to provide cross-serogroup protection, and the ability to express immune-enhancing molecules that promote recognition by the immune system. Six Salmonella subunit vaccine candidates were developed in either attenuated S. Enteritidis (SE) or S. Typhimurium (ST) that cell-surface express antigenic epitopes of high mobility group box 1 immune-enhancing sequence (H), peptidoglycan associated lipoprotein (P), and Omp18 protein Cj0113 ( SE-CPH reduced SH recovery (P < 0.05) on d 18, 2.75 ± 0.05 log 10 cfu, and d 25, 1.89 ± 0.43 log 10 cfu, as compared to control chickens at 5.6 ± 0.37 (d 18) and 3.98 ± 0.5 log 10 cfu (d 25). The results of these experiments suggest that cross-serogroup protection is possible using these SE and ST-vectored subunit vaccines.
INTRODUCTION
Cases of salmonellosis are most commonly linked to contaminated eggs and poultry products, which are the leading source of Salmonella outbreaks in the United States and Europe. In addition, Campylobacter continues to be a food safety concern with over 18 million annual cases of gastroenteritis associated with the pathogen in the United States (Kaakoush et al., 2015) . As a result, the poultry industry has sought multiple ante mortem intervention strategies that include increased biosecurity, therapeutic antibiotics, competi-C 2017 Poultry Science Association Inc. Received January 12, 2017. Accepted May 10, 2017. 1 Corresponding author: bielke.1@osu.edu tive exclusion and probiotics, and vaccination. The two most common types of vaccines used in animal agriculture are killed whole-cell bacterins and live attenuated vaccines, both of which are useful in many applications, but do have limitations (Barrow, 2007) . Killed vaccines have been primarily used to protect against systemic infections, and although they have been known to reduce colonization and shedding, the protection provided by these vaccines has only limited ability to stop mucosal colonization (Nakamura et al., 2004; Deguchi et al., 2009 ). Additionally, they often require injection, which is not practical in the poultry industry due to the large number of animals that would require vaccination.
Live attenuated vaccines have ability to colonize the gut which may provide a mucosal immune response, as well as potentially competitively exclude 4352 heterologous strains of Salmonella from colonizing the gastrointestinal tract (GIT) (Holt and Gast, 2004; Van Immerseel et al., 2005; Barrow, 2007) . The adaptive immune response elicited by live vaccines is composed of a humoral as well as cell-mediated response similar to that seen in a natural infection (Mastroeni et al., 2001; Van Immerseel et al., 2005; Barrow, 2007) . This is in contrast to a killed vaccine, which primarily stimulates a humoral response. After vaccination, protection against homologous strains of Salmonella is almost complete (Chacana and Terzolo, 2006; Ghany et al., 2007) , but often little protection is afforded against a challenge by a heterologous serotype (Barrow, 2007; Young et al., 2007) . Thus cross-serotype protection, especially against minor serovars for which live attenuated vaccines are not available, has become a desirable aspect of Salmonella vaccines.
Subunit vaccines, which are genetically modified bacteria containing antigens against multiple pathogens and include attenuated live recombinant bacterialvectored vaccines have become viable options for animal agriculture vaccines as a result of recent advances in the field. Many research programs have modified multiple species of bacteria including Salmonella Typhimurium, Salmonella Enteritidis, Salmonella Typhi, Escherichia coli, Lactobacillus casei, Lactobacillus reuteri, Bacillus subtilis, and Bacillus thuringiensis, to name a few, to express protein antigens against bacterial, viral, and protozoal pathogens as well as toxins (Yang et al., 1990; Tacket et al., 1997; Duc and Cutting, 2003; Arnold et al., 2004; Mauriello et al., 2004; Zhang et al., 2006; Kajikawa et al., 2007; Wu and Chung, 2007; Deguchi et al., 2009) . These vaccines have an advantage over other types of vaccines in that they are able to be delivered via nasal, ocular, or oral administration, which may enhance mucosal immune response, the primary surface through which most pathogens invade.
Presently, in these experiments, multiple Salmonella subunit vaccines were developed to test possibility of providing cross-serogroup protection, plus protection against Campylobacter in order to improve vaccination strategies and effectiveness in the poultry industry, by providing an orally effective vaccine. Antigenic epitopes for insertion into vaccines were selected for inclusion based on predicted immunogenicity and B-cell activation, external cell wall expression, and homology among species or serovars. These vaccines were modified to insert highly conserved antigenic epitopes of peptidoglycan associated lipoprotein (PAL) of Salmonella and Campylobacter Omp18 protein Cj0113 (CJ0113; (Layton et al., 2011) . Additionally, a portion of chicken high mobility group box 1 protein (HMGB1) was included as an immune enhancing molecule to promote uptake by antigen presenting cells. The goal of these experiments were to show ability of vaccination to protect against challenge with Salmonella Heidelberg for testing of cross-serogroup protection with S. Enteritidisvectored vaccine candidates.
MATERIALS AND METHODS

Vaccine Construction
Overview of Mutational Strategy. The strategy used for construction of the vaccine strains in both S. Enteritidis and S. Typhimurium backgrounds was previously described (Cox et al., 2007; Wolfenden et al., 2010) . Briefly, in this two-step mutagenesis process, the I-SceI site/kanamycin resistance (Km r ) cassette was first inserted into the lamB gene by Red recombinasemediated homologous recombination via selection with kanamycin. Then, this mutation was replaced by the linear fragment carrying desired insertion sequence encoding combinations of PAL, CJ0113, and HMGB1 sequences in three different orders (Figure 1 ). For the selection of the desired mutant, the linear PCR product carrying the desired insertion sequence was transformed simultaneously with the plasmid, pBC-I-SceI, expressing I-SceI homing endonuclease enzyme used for counter-selection against the strains carrying I-SceI site (Cox et al., 2007) .
Bacterial Strains and Culture Conditions. SE164 strain, which carries I-SceI/Km r cassette in the loop 9 region in lamB gene and also contains plasmid pKD46, was used for construction of the three S. Enteritidis (SE) vaccine strains in this study (Cox et al., 2007) . For vaccines based on S. Typhimurium background, the wild type S. Typhimurium 110 (ST) was used first for construction of the attenuated strain with deletion in aroA gene, and the I-SceI/Km r cassette was inserted into the loop 9 region of lamB gene via Red recombination in this study as previously described (Cox et al., 2007) . Luria-Bertani (LB) media was used for routine growth of Salmonella cells, and 2× YT broth (Thermo Fisher Scientific, Cat. #22712-020, Waltham, MA) for the preparation of electro-competent cells. Super Optimal broth with Catabolite repression (SOC) media (Invitrogen, Carlsbad, CA) was used for phenotypic expression after electroporation. The following antibiotics were added to the media when appropriate: ampicillin (Amp) at 100 μg/mL, kanamycin (Km) at 50 μg/mL, and chloramphenicol (Cm) at 25 μg/mL.
Plasmids. Plasmids pKD46 used in the present study was described previously (Datsenko and Wanner, 2000; Cox et al., 2007) . Plasmid pKD46 encodes Red recombinase enzymes that mediate homologous recombination of incoming linear DNA with chromosomal DNA. This plasmid also contains the ampicillin resistance gene (Amp r ) and has a temperature-sensitive replicon, requiring 30
• C for maintenance of the cell. Plasmid pBC-I-SceI expresses the I-SceI enzyme, which cleaves the rare SceI sites of 18 bp long (Kang et al., 2004; Cox et al., 2007) . Also, plasmid pBC-I-SceI carries the chloramphenicol resistance (Cm r ). Plasmids pCJ0113, pPAL, and pHMGB1, which carry individual epitope sequences for portions of CJ0113, PAL, and HMGB1, respectively, were synthesized by GeneScript (Piscataway, NJ). These plasmids were used as templates for PCR amplification of respective DNA fragments.
PCR. All primers used for PCR are listed in Table 1 . Typical PCR conditions consisted of approximately 0.1 μg of purified genomic, plasmid or PCR-generated DNA, 10× cloned Pfu polymerase buffer, 5 U Pfu polymerase (Stratagene La Jolla, CA), 1 mM dNTPs (GE Healthcare Bio-Sciences Corp., Piscataway, NJ), 1.2 μM each primer in a total volume of 50 μL. The DNA engine thermal cycler (Bio-Rad, Hercules, CA) was used with the following amplification conditions: 94
• C for 2 minutes; 30 cycles of 94
• C sec for 30 sec, 58
• C for 60 sec, 72
• C for 90 sec per 1 kb; and 72
• C for 10 minutes for final extension. Each PCR product was gel-purified (Qiagen, Valencia, CA) and eluted in 20 μL elution buffer (EB) buffer for preparation of templates used in overlapping extension PCR. For the linear overlapping PCR product, the product was gel-purified and eluted in 50 μL EB buffer, ethanol precipitated, and resuspended in 5 μL of ddH 2 O for concentration, which then was used for electroporation. Transformation. Transformation of pKD46 into S. Typhimurium was the first step carried out so that Red recombinase enzymes could be used for mediating recombination between a linear PCR product and chromosomal DNA. Plasmid pKD46 was used for transformation into S. Typhimurium 110 by electroporation. Briefly, cells were inoculated into 10 mL of 2× YT broth and grown at 37
• C overnight. Then 100 μL of overnight culture was re-inoculated into 10 mL fresh 2× YT broth at 37
• C for 3 to 4 hours until OD 600 reached 0.8 to 1.0. Then, the cells were heated at 50
• C for 25 minutes to inactivate host restriction system temporarily. Cells were washed five times in 10% glycerol and resuspended in 60 μL of 10% glycerol. Cells were then electrically pulsed at 2,400 to 2,450 kV for 1 to 6 ms, followed by shaking in SOC medium (500 μL) for 2 to 3 hours at 30
• C and plated on LB agar media with ampicillin. S. Typhimurium transformants carrying pKD46 were maintained at 30
• C. When these transformants were prepared for Red recombination-based homologous recombination through electroporation, all steps were the same except that 15% arabinose was added to induce Red recombinase enzymes one hour prior to washing, and cells did not undergo the 50
• C heating step. Construction of Intermediate Construct Carrying I-SceI/Km r . Construction of SE mutant strain carrying the I-SceI/Km r fragment in the loop 9 region of the lamB gene and plasmid pKD46 (SE164) was described previously (Cox et al., 2007) . The equivalent intermediate construct for S. Typhimurium 110 was constructed essentially by the same method. However, prior to insertion of the I-SceI/km r , the aroA gene in S. Typhimurium was deleted as described previously (Cox et al., 2007) for virulence attenuation. Briefly, the deletion aroA gene was performed by inserting the Km r gene in place of and thereby deleting aroA. This was done by first by amplifying the aroA upstream (primers aroA-1F and aroA-1R), and downstream (aroA-2F and aroA-2R) sequences, which was joined with the Km r cassette amplified from plasmid pKD4 using primers Kan 3F and Kan 3R (Table 1 ). This deletion cassette constructed by joining the 3 fragments by overlapping PCR was transformed into S. Typhimurium 110 strain, followed by selection with kanamycin. Additionally, the previously described pCP20 was introduced into ΔaroA cells to remove the Km r gene from the aroA gene locus (Cox et al., 2007) .
Construction of the Vaccine Strains SurfaceDisplaying Three Epitopes. The first step was to amplify the linear PCR fragments that carry the DNA sequences of the three epitopes PAL (P), CJ0113 (C) and HMGB1 (H) in different orders along with four spacers of Serine residues as shown in Figure 1 . Different arrangements of C, P, and H were to increase the possibility of proper folding, based on charge of the proteins, on the cell surface. Due to unpredictable charge of surrounding proteins which may interfere with expression of the inserted genes on the cell surface, multiple sequences increased the probability of successful presentation. The DNA codons for encoding the amino acids for the epitopes as well as Serine (TCC) were optimized for the most frequently used codons in Salmonella proteins (Burns and Beacham, 1985) . The designs and DNA sequence of the primers are shown in Figure 1 and Table 1, respectively. To simplify the construction steps, the same lamB up and lamB dn fragments were commonly used for construction of all 3 epitope cassettes. The sequence of CJ0113 in the cassette CHP and CPH or HMGB1 in the cassette HCP was amplified to include a region overlapping with the 3 end of the lamB up fragment. The sequence of PAL in the cassette CHP, and HCP or HMGB1 in the cassette CPH was amplified to include a region overlapping with the 5 end of the lamB down fragment. For each cassette three individual fragments were separately amplified from relevant plasmids (pCJ0113, pPAL, and pHMGB1), and were joined together by overlapping PCR. Then, each of the overlapping PCR products was joined to the common lamB up and lamB dn fragments by overlapping PCR to obtain the epitope cassettes that consist of lamB up-3 epitopes-lamB dn as shown in Figure 1 .
Genomic Replacement of I-SceI/Km r with Three Epitope Sequences. The resulting epitope cassettes and the plasmid pBC-I-SceI (at a molar ratio of approximately 40:1) were simultaneously electroporated into the competent cells of SE and ST background, which carried the I-SceI/Km r cassette in loop 9 of the lamB gene and plasmid pKD46. Colonies for each recombination mutation were chosen according to the ability to grow on Cm plates, but not on Km plates, due to the replacement of Sce-I-Km r cassette with the incoming epitope cassette. Finally the vaccine candidates were verified by DNA sequencing using primers lamb-3f and lamb-3r, which are located outside of the loop 9 up and dn regions. After confirmation by DNA sequencing, external expression of inserted antigenic sequences was confirmed by antibody agglutination with anti-PAL, CJ0113, and HMGB1 rabbit hyper-immune serum (methods not described here).
Experimental Design
In all in vivo challenge experiments, chickens were raised in floor pens with wood shavings and were separated by solid panel walls to prevent crosscontamination with live vectored vaccines. Broilers were provided feed and water ad libitum, and diet was formulated to meet or exceed nutritional requirements. Ambient temperature in the rearing facility was maintained at age-appropriate levels. All experiments were conducted under University of Arkansas Institutional Animal Care and Use Committee approved protocols.
Bacterial Cultures. Challenge strain of Salmonella Heidelberg (SH) was a field isolate confirmed to serogroup level by agglutination with O factor antiserum (Becton, Dickinson and Co., Sparks, MD) and typed by the National Veterinary Services Laboratories (Ames, IA). Cultures were prepared by growth in tryptic soy broth (TSB, Becton, Dickinson and Co., Sparks, MD) for approximately 8 h each for three passages by transferring 1% of culture to fresh TSB. The cells were washed three times in sterile saline by centrifugation (1,864 × g), and approximate concentration of the stock solution was determined spectrophotometrically. The stock solution was serially diluted and confirmed by colony counts of three replicate samples plated on XLT4 agar (Becton, Dickinson and Co., Sparks, MD) plates. For cecal recovery of SH after challenge, birds were killed by CO 2 inhalation and entire ceca aseptically removed. Samples were diluted 1:4 w:v in sterile saline, 100 μL removed for cfu determination by serial plating on XLT4 agar, while the remaining portion was enriched in tetrathionate broth (Becton, Dickinson and Co., Sparks, MD) by overnight incubation at 37
• C, followed by plating on XLT4 agar.
Challenge strain of Campylobacter jejuni was a field isolate confirmed by culture techniques and microscopic observations of typical Campylobacter morphology. For recovery, approximately 6 cm of the lower ileum was aseptically collected into sterile sample bags, diluted 1:4 w:v in sterile saline, then stomached for 10 s, plus a portion of diluted ceca supernatant (above) was serially diluted. Intestinal samples were directly plated onto selective Campylobacter chromogenic agar (R-F Labs, Downers Grove, IL). After incubation for 48 h at 42
• C under microaerophilic conditions, colonies consistent with Campylobacter were enumerated. Experiment 3. In the final experiment, only SE-CPH vaccine was tested against SH challenge with a spray vaccination instead of oral gavage to simulate the conditions likely to be applied in a hatchery setting. On day of hatch, 50 chicks per group were placed in a cardboard hatchery transport box, blocked off to provide chicks with typical spacing, which was then placed into a commercial vaccine spray chamber that was loosely covered with plastic on each end to prevent escape of sprayed vaccine. Control chicks were sprayed with saline carrier and an estimated dose of 1.6 × 10 7 cfu/chick was sprayed into the cabinet for treated chicks. Particle size of the spray was confirmed by collection of spray onto a microscope slide and measured at ∼6 μm droplets. 
Statistical Analysis.
Numerical data from all experiments were subjected to ANOVA (SAS Institute, 2002) . log 10 cfu values per sample are expressed as mean ± standard error and deemed significant at P ≤ 0.05. The data were also subjected to mean separation using Duncan's multiple range test of significance.
RESULTS
Construction and Confirmation of the Vaccine Strains
After electroporation, colonies were chosen as the candidates according to the ability to grow on Cm plates but not on Km plates. Colony PCR was con- On day of hatch and day 14, chickens were vaccinated with respective antigen-vectored vaccines, challenged with 6 × 10 6 cfu/chick of S. Heidelberg on d 17, and ceca were collected for recovery 5 and 10 days post-challenge (DPC). ducted using candidate colonies with lamb-3f and lamb3r primers that anneal outside of the lamB up and lamB dn regions. When the expected size of the PCR products of ∼726 bp was confirmed by gel electrophoresis, the PCR product was gel purified for DNA sequencing. The colonies for which DNA sequencing data confirmed the insertion of the correct sequence for each epitope cassette in the correct location in the lamB loop 9 region were stored at −80
• C with 30% glycerol.
Experiment 1
Five days post-SH challenge (DPC), negative control birds tested positive at a mean level of 1.19 ± 0.26 log 10 cfu/g of ceca, whereas SE-CPH vaccinated chickens had a recovery level of only 0.34 ± 0.23 log 10 cfu/g of ceca which was significantly lower when the groups were directly compared by Student t test (Table 2) . Levels of SH recovered from ceca of other challenged groups at 5 DPC were 0.69 ± 0.53 log 10 cfu/g (SE-HCP), 0.64 ± 0.48 log 10 cfu/g (SE-CHP), 3.02 ± 0.57 log 10 cfu/g (ST-CPH), 0.94 ± 0.63 log 10 cfu/g (ST-HCP), and 0.68 ± 0.28 log 10 cfu/g (ST-CHP). Ten DPC, ST-HCP vaccinated group dropped SH level to 0.51 ± 0.26 log 10 cfu/g, which was significantly lower than the control group, by direct comparison via Student t test, at 1.36 ± 0.23 log 10 cfu/g. Levels of SH recovery from the SE-CPH rose to 0.40 ± 0.40 log 10 cfu/g, which was different from control group (P = 0.0514) by direct comparison.
Experiment 2
After day of hatch vaccination, chickens were challenged with SH, followed by detection of the challenge strain 21 and 28 DPC. At 21 DPC vaccine candidate SE-CPH was the only vaccination group to have significantly lower recovery of SH from the ceca than negative control at 4.71 ± 0.55 vs. 6.16 ± 0.13 log 10 Table 3 . Recovery of Salmonella Heidelberg from ceca after vaccination by oral gavage on day of hatch, Experiment 2. cfu/g (Table 3 ). Though the difference between 21 and 28 DPC was less than 0.1 log 10 change for SE-CPH vaccine group, negative control recovery dropped to 5.11 ± 0.59 log 10 cfu/g and the significant difference did not persist. Campylobacter recovery was highest in the ceca (Figure 2) , with levels ranging from 7.14 ± 0.29 log 10 cfu/g after SE-CPH vaccination to 7.70 ± 0.29 log 10 cfu/g in the non-vaccinated control group. Levels of Campylobacter recovered in the ileum were much lower with a range of 0.17 ± 0.17 log 10 cfu/g recovered from SE-CHP vaccinated birds to 1.05 ± 0.57 log 10 cfu/g in SE-HCP vaccinated birds. There were no statistical differences among any of the groups for Campylobacter levels.
Experiment 3
Only SE-CPH vaccine candidate was tested in Experiment 3, with a time course study to evaluate persistence of protection. Four and 7 DPC, recovery of SH in vaccinated chickens were 2.7 ± 0.0 log 10 cfu/g and 1.89 ± 0.41 log 10 cfu/g, respectively. Compared to recovery in negative control group, at 5.61 ± 0.36 log 10 cfu/g (4 DPC) and 3.98 ± 0.47 log 10 cfu/g (7 DPC), a significant reduction was observed (Figure 3) . However, by 12 DPC, the difference in cecal SH recovery was reduced to 3.93 ± 0.66 log 10 cfu/g in negative control and 3.01 ± 0.92 log 10 cfu/g in vaccinated treatment, which was not significantly different.
DISCUSSION
Construction of all vaccine strains described in the study took place essentially by the method previously established in our laboratory (Cox et al., 2007) . Once the epitope cassettes of different designs were prepared by overlapping PCR, the construction of the vaccine strains carrying the epitope cassettes was a straightforward process. In the final constructs, the antibiotic resistance cassette (Km r cassette) was removed and replaced by the desired epitope cassette, making them free of antibiotic markers. Once the final constructs were confirmed at DNA sequence level, the functional expression of each of the epitopes was also confirmed by standard antibody agglutination assays with hyperimmune sera against each of the antigens.
The first vaccine experiment evaluated six different SE-and ST-vectored vaccines, each containing CJ0113, PAL, and HMGB1 genetic inserts in different patterns, against SH challenge. Five days after challenge SE-CPH vaccinated chickens had reduced recovery of SH from ceca, with a trend in reduction ten DPC (P = 0.0514) and 0.96 log 10 cfu/g reduction in cecal recovery (Table 2). Vaccination with ST-HCP also resulted in reduced recovery of SH from cecal tonsils, when compared directly to the negative control group, but only at ten DPC. Given the overall lack of reduction in SH recovery 5 DPC with ST-vectored vaccine candidates, they were not carried forward in subsequent experiments. Although not all of the SE-vectored strains were effective in giving a significant reduction in SH detected, there was some numerical suggestion, and all three vaccines were re-evaluated. As suggested previously, this lack of effectiveness could be related to natural folding and expression of the antigen epitopes on the cell surface in a manner that inhibited antigenicity or immunogenicity. Experiment 2 tested only SE-vectored vaccine candidates against SH challenge and recovery at 21 and 28 days post-challenge. Only SE-CPH resulted in decreased cecal recovery of SH with a 1.45 log 10 cfu/g reduction, and no vaccine group had lower recovery by 28 days post-infection (Table 3) . These results at least partially confirmed the results of Experiment 1 in that only SE-CPH was able to provide protection, evidenced by the >96% decrease in SH at 21 days post-challenge, and that SE-HCP and SE-CHP were not as robust at providing protection against colonization. This study also evaluated effect of vaccination against Campylobacter jejuni challenge, with samples collected from ileum and ceca 28 days post-challenge. Contrary to previous studies utilizing CJ0113 antigen (Layton et al., 2011) , no statistically significant reduction of Campylobacter was observed (Figure 2) . However, these results are not entirely inconsistent with Layton et al. (Layton et al., 2011) which reported efficacy of an SE-vectored CJ0113 vaccine against C. jejuni recovery in ileum of chickens. In that report, C. jejuni was detected by quantitative PCR techniques with a limit of detection at 1.0 log 10 cfu. Thus, had the present study followed the same detection techniques, it is unlikely that C. jejuni would have been detected in chickens vaccinated with SE-CHP, but it should be noted that ileum levels of C. jejuni in the negative control group also would have been low, and were much lower than those reported by Layton et al., (2011) . Recent changes in culture detection techniques and better understanding of Campylobacter infection in poultry, such as ceca as the primary site of infection versus ileum (Chaloner et al., 2014; Bahrndorff et al., 2015; Chintoan-Uta, 2016) , likely account for differences between this and the previous report. It should also be noted that the previous research report inserted a CD154 immune-enhancing molecule instead of the HMGB1 molecule used in these studies, which may have accounted for differences.
The final experiment investigated the ability of a single day of hatch vaccination by SE-CPH to reduce levels of SH in ceca at four, seven, and twelve days postchallenge. Early recovery time points, four and seven DPC, had significantly lower levels of SH in vaccinated groups. However, a decline in levels in negative control combined with an increase in SE-CPH vaccinated group, negated this difference by 12 DPC (Figure 3) . Re-infection of GIT is possible through coprophagic activity in poultry and these data suggest that a single vaccination likely does not provide long-term immune protection against re-infection from exposure later in life.
The purpose of testing protection of SE-vectored vaccination against SH was to determine the ability of the vaccine to provide cross-serogroup protection in broilers because 92% of Salmonella positive samples from broilers analyzed under the Food Safety and Inspection Service HACCP program in 2014 were represented across three different serogroups, suggesting that a vaccine capable of providing protection across these serogroups would have great impact on reduction of Salmonella on poultry products (United Stated Department of Agriculture, 2016). Though S. Kentucky was the highest isolated serotype, it is not among serotypes commonly associated with human illness. Thus, SH was selected due to the ability to prove both crossserotype and serogroup protection among ST or SE vaccinated chickens. These studies showed that vaccination with SE-vectored subunit vaccine containing the highly conserved antigen PAL was able to confer protection against SH challenge for up to 21 days post-infection. Salmonella Typhimurium vector was able to reduce SH recovery up to 10 days post-infection in the single experiment tested.
Subunit vaccines expressing cross-protective antigens may be useful for the poultry industry due to ability to reduce levels of Salmonella across multiple serotypes and serogroups, thus effectively reducing levels of Salmonella on animals as they enter processing facilities. The studies presented here were primarily aimed at the ability of a highly conserved antigen, PAL, expressed in a double-attenuated SE (serogroup D) strain to provide protection against a SH (serogroup B) strain, as well as an attenuated ST strain to provide protection against SH. Results indicate that live attenuated vaccination with a serogroup D Salmonella Enteritidis subunit vaccines containing antigen PAL and the immune enhancing molecule HMGB1 can reduce cecal levels of serogroup B Salmonella Heidelberg, suggesting that cross-serogroup protection against Salmonella infection in poultry is achievable.
